Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease

Diabetes Care

Volumn 39, Issue 10, 2016, Pages 1684-1692

  Inzucchi, Silvio E ^a   Viscoli, Catherine M ^a   Young, Lawrence H ^a   Furie, Karen L ^b   Gorman, Mark ^c   Lovejoy, Anne M ^a   Dagogo Jack, Samuel ^d   Ismail Beigi, Faramarz ^e   Korytkowski, Mary T ^f   Pratley, Richard E ^g   Schwartz, Gregory G ^h   Kernan, Walter N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g FLORIDA HOSPITAL   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BRAIN ISCHEMIA; CANCER INCIDENCE; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METABOLISM; OUTCOME ASSESSMENT; PREVALENCE; RISK FACTOR; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; AGED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; THIAZOLIDINEDIONES;

EID: 84988931428     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0798     Document Type: Article

References (38)

1. International Diabetes Foundation. IDF Diabetes Atlas. 7th ed. Available from www .diabetesatlas.org. Accessed 9 April 2016
2. Inzucchi SE, Sherwin RS. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2005;34:199-219, viii
3. Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-2676
4. DeFronzo RA, Tripathy D. Skeletalmuscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009;32(Suppl. 2):S157-S163
5. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
6. Viscoli CM, Brass LM, Carolei A, et al.; IRIS Trial investigators. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 2014;168:823-829
7. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
10. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263
11. FDA Drug Safety Communication. Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [Internet], 2013. Available from http://www.fda .gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm226257.htm. Accessed 9 April 2016
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5-S10
13. Tonyushkina K, Nichols JH. Glucose meters: A review of technical challenges to obtaining accurate results. J Diabetes Sci Technol 2009;3:971-980
14. Cox DR. Regression models and life-tables. J R Stat Soc [Ser A] 1972;34:187-202
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
16. Hochberg Y. A sharper Bonferroni Procedure for multiple tests of significance. Biometrika 1988;75:800-802
17. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752
18. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2016;39(Suppl. 1):S13-S22
19. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF Consultation. [Internet], 2006. Available from http:// www.who.int/diabetes/publications/Definition %20and%20diagnosis%20of%20diabetes-new .pdf. Accessed 9 April 2016
20. Knowler WC, Hamman RF, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-1156
21. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-1105
22. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOWStudy. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
23. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803
24. DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care 2011;34:1265-1269
25. Tripathy D, Schwenke DC, Banerji M, et al. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from ACT NOW. J Clin Endocrinol Metab 2016; 101:2056-2062
26. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links.The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
27. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 2014;10:293-302
28. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
29. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
30. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013;33:393-399
31. Cheang WS, Tian XY, Wong WT, Huang Y. The peroxisome proliferator-activated receptors in cardiovascular diseases: Experimental benefits and clinical challenges. Br J Pharmacol 2015;172:5512-5522
32. Castrillo A, Tontonoz P. PPARs in atherosclerosis: The clot thickens. J Clin Invest 2004; 114:1538-1540
33. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf 2009;32: 187-202
34. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007;370: 1129-1136
35. Fadini GP, Avogaro A, Degli Esposti L, et al.; OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: A retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J 2015;36:2454-2462
36. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015;314:265-277
37. Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: Population based cohort study. BMJ 2016;352:i1541
38. Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: Findings from a large pharmacy claims database. Diabetes Care 2015;38:604-609